Christopher Jahraus, MD
Radiation Oncology · Alabaster, ALNPI 1700814753
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Elekta, Inc. accounts for 91.9% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2022 at $10,133 and has fallen 97.6% since, to $240 in 2025. Among radiation oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $175.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$26K
- Amgen$258
- Bristol Myers Squibb$239
- Novartis$194
- Histosonics, Inc.$150
- AstraZeneca$150
- plus $1K from 27 others
What the payments were for
- Consulting fees$14,55051%
- Speaking & faculty fees$3,00011%
- Travel & lodging$7,44226%
- Food & beverage$3,33212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elekta, Inc. | 24 | $26,041 |
| Amgen | 16 | $258 |
| Bristol Myers Squibb | 15 | $239 |
| Novartis | 14 | $194 |
| Histosonics, Inc. | 1 | $150 |
| AstraZeneca(2 entities) | 9 | $150 |
| Tesaro, Inc. | 7 | $135 |
| Lilly USA, LLC | 8 | $104 |
| Merck | 7 | $104 |
| E.r. Squibb & Sons, L.L.C. | 8 | $100 |
| Novocure Inc. | 3 | $79 |
| Johnson & Johnson(2 entities) | 5 | $73 |
| Regeneron Healthcare Solutions, Inc. | 5 | $70 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $63 |
| Ipsen Biopharmaceuticals, Inc | 3 | $60 |
| Incyte Corporation | 3 | $49 |
| Daiichi Sankyo Inc. | 3 | $47 |
| Bayer | 3 | $45 |
| Sanofi | 2 | $43 |
| Kyowa Kirin, Inc. | 3 | $43 |
| Pfizer | 3 | $41 |
| Eisai Inc. | 2 | $33 |
| Verastem, Inc. | 2 | $28 |
| AbbVie | 1 | $26 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Exelixis Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Covidien LP | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Seagen Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,325 in reported general payments places this provider in the 95th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 20 | $1,022 |
| Tamsulosin Hcl | 52 | $719 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Alabaster
- Alexander WhitleyMontgomery$441K
- Drexell BoggsBirmingham$35K
- Christopher WilleyBirmingham$13K
- Adam KoleBirmingham$11K
- William HixsonFairhope$10K
- John GleasonHuntsville$9K
- Andrew McDonaldBirmingham$8K
- Hoyt ChildsHuntsville$7K
- James TuckerTuscaloosa$6K
- Harry McCartyHuntsville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.